FOXO3 lies within the 6q21 locus that is frequently lost in prostate cancer [160], and reduced FOXO3 (also FOXO3a) activity via peptide driven inhibition is reported to accelerate prostate cancer progression in the transgenic adenocarcinoma mouse prostate (TRAMP) neuroendocrine prostate cancer model [161]. Here, FOXO3 is linked to adenocarcinoma.